Veterinary Medicines

CANIGEN MHA2PLR

Suspended
  • Canine distemper virus, strain Lederle VR128, Live
  • Canine adenovirus 2, strain Manhattan, Live
  • Canine parvovirus, strain Cornell 780916, Live
  • Leptospira interrogans, serogroup Canicola, serovar Canicola, strain 601903, Inactivated
  • Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain 601895, Inactivated
  • Rabies virus, strain VP12, Inactivated
Download as PDF

Product identification

Medicine name:
CANIGEN MHA2PLR
Active substance:
  • Canine distemper virus, strain Lederle VR128, Live
  • Canine adenovirus 2, strain Manhattan, Live
  • Canine parvovirus, strain Cornell 780916, Live
  • Leptospira interrogans, serogroup Canicola, serovar Canicola, strain 601903, Inactivated
  • Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain 601895, Inactivated
  • Rabies virus, strain VP12, Inactivated
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Canine distemper virus, strain Lederle VR128, Live
    5.00
    cell culture infective dose 50
    /
    1.00
    Dose
  • Canine adenovirus 2, strain Manhattan, Live
    6.00
    cell culture infective dose 50
    /
    1.00
    Dose
  • Canine parvovirus, strain Cornell 780916, Live
    7.00
    cell culture infective dose 50
    /
    1.00
    Dose
  • Leptospira interrogans, serogroup Canicola, serovar Canicola, strain 601903, Inactivated
    80.00
    percentage protection
    /
    1.00
    Dose
  • Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain 601895, Inactivated
    80.00
    percentage protection
    /
    1.00
    Dose
  • Rabies virus, strain VP12, Inactivated
    1.00
    international unit(s)
    /
    1.00
    Dose
Pharmaceutical form:
  • Lyophilisate and suspension for suspension for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AJ05
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Suspended
Authorised in:
  • Spain
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Virbac Espana S.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Virbac
Responsible authority:
  • The Spanish Agency Of Medicines And Medical Devices
Authorisation number:
  • 3219 ESP
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Spanish (PDF)
Published on: 9/11/2022
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Spanish (PDF)
Published on: 9/11/2022
Download

Labelling

This document does not exist in this language (English). You can find it in another language below.
Spanish (PDF)
Published on: 9/11/2022
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."